22 results on '"Van Eldik, Linda J."'
Search Results
2. Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia
- Author
-
Braun, David J., Bachstetter, Adam D., Sudduth, Tiffany L., Wilcock, Donna M., Watterson, D. Martin, and Van Eldik, Linda J.
- Published
- 2019
- Full Text
- View/download PDF
3. Microglial-associated responses to comorbid amyloid pathology and hyperhomocysteinemia in an aged knock-in mouse model of Alzheimer’s disease
- Author
-
Braun, David J., Dimayuga, Edgardo, Morganti, Josh M., and Van Eldik, Linda J.
- Published
- 2020
- Full Text
- View/download PDF
4. Effects of advanced age upon astrocyte-specific responses to acute traumatic brain injury in mice
- Author
-
Early, Alexandria N., Gorman, Amy A., Van Eldik, Linda J., Bachstetter, Adam D., and Morganti, Josh M.
- Published
- 2020
- Full Text
- View/download PDF
5. Deletion of p38α MAPK in microglia blunts trauma-induced inflammatory responses in mice
- Author
-
Morganti, Josh M., Goulding, Danielle S., and Van Eldik, Linda J.
- Published
- 2019
- Full Text
- View/download PDF
6. Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human β-amyloid in a murine model of neuroinflammation
- Author
-
Craft, Jeffrey M., Van Eldik, Linda J., Zasadzki, Magdalena, Hu, Wenhui, and Watterson, D. Martin
- Published
- 2004
- Full Text
- View/download PDF
7. ApoE and Aβ1–42 interactions: Effects of isoform and conformation on structure and function
- Author
-
Manelli, Arlene M., Stine, W. Blaine, Van Eldik, Linda J., and LaDu, Mary Jo
- Published
- 2004
- Full Text
- View/download PDF
8. Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against β-amyloid induced injury: A foundation for future medicinal chemistry efforts focused on targeting Alzheimer’s disease progression
- Author
-
Watterson, D. Martin, Velentza, Anastasia V., Zasadzki, Magdalena, Craft, Jeffrey M., Haiech, Jacques, and Van Eldik, Linda J.
- Published
- 2003
- Full Text
- View/download PDF
9. First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
- Author
-
Van Eldik, Linda J., Sawaki, Lumy, Bowen, Karen, Laskowitz, Daniel T., Noveck, Robert J., Hauser, Byron, Jordan, Lynn, Spears, Tracy G., Wu, Huali, Watt, Kevin, Raja, Shruti, Roy, Saktimayee M., Watterson, D. Martin, and Guptill, Jeffrey T.
- Subjects
- *
ENDOTOXINS , *PHARMACOKINETICS , *CYTOKINES , *BRAIN injuries , *LABORATORY safety , *VOLUNTEERS - Abstract
MW01‐6‐189WH (MW189) is a novel central nervous system–penetrant small‐molecule drug candidate that selectively attenuates stressor‐induced proinflammatory cytokine overproduction and is efficacious in intracerebral hemorrhage and traumatic brain injury animal models. We report first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1 studies to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending intravenous doses of MW189 in healthy adult volunteers. MW189 was safe and well tolerated in single and multiple doses up to 0.25 mg/kg, with no clinically significant concerns. The most common drug‐related treatment‐emergent adverse event was infusion‐site reactions, likely related to drug solution acidity. No clinically concerning changes were seen in vital signs, electrocardiograms, physical or neurological examinations, or safety laboratory results. PK analysis showed dose‐proportional increases in plasma concentrations of MW189 after single or multiple doses, with approximately linear kinetics and no significant drug accumulation. Steady state was achieved by dose 3 for all dosing cohorts. A pilot pharmacodynamic study administering low‐dose endotoxin to induce a systemic inflammatory response was done to evaluate the effects of a single intravenous dose of MW189 on plasma cytokine levels. MW189 treatment resulted in lower levels of the proinflammatory cytokine TNF‐α and higher levels of the anti‐inflammatory cytokine IL‐10 compared with placebo treatment. The outcomes are consistent with the pharmacological mechanism of MW189. Overall, the safety profile, PK properties, and pharmacodynamic effect support further development of MW189 for patients with acute brain injury. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Targeting innate immunity for neurodegenerative disorders of the central nervous system
- Author
-
Andreasson, Katrin I., Bachstetter, Adam D., Colonna, Marco, Ginhoux, Florent, Holmes, Clive, Lamb, Bruce, Landreth, Gary, Lee, Daniel C., Low, Donovan, Lynch, Marina A., Monsonego, Alon, O’Banion, M. Kerry, Pekny, Milos, Puschmann, Till, Russek-Blum, Niva, Sandusky, Leslie A., Selenica, Maj-Linda B., Takata, Kazuyuki, Teeling, Jessica, Town, Terrence, and Van Eldik, Linda J.
- Subjects
0301 basic medicine ,Central Nervous System ,Central nervous system ,Disease ,Blood–brain barrier ,Biochemistry ,Article ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,medicine ,Animals ,Humans ,Neuroinflammation ,Inflammation ,Innate immune system ,Microglia ,business.industry ,TREM2 ,Neurodegenerative Diseases ,medicine.disease ,Immunity, Innate ,030104 developmental biology ,medicine.anatomical_structure ,Astrocytes ,Immunology ,Alzheimer's disease ,business ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. This mini review series originated from the 4th Venusberg Meeting on Neuroinflammation held in Bonn, Germany, 7-9th May 2015, presenting updates on innate immunity in acute brain injury and chronic neurodegenerative disorders, such as traumatic brain injury and Alzheimer disease, on the role of astrocytes and microglia, as well as technical developments that may help elucidate neuroinflammatory mechanisms and establish clinical relevance. In this meeting report, a brief overview of physiological and pathological microglia morphology is followed by a synopsis on PGE2 receptors, insights into the role of arginine metabolism and further relevant aspects of neuroinflammation in various clinical settings, and concluded by a presentation of technical challenges and solutions when working with microglia and astrocyte cultures. Microglial ontogeny and induced pluripotent stem cell-derived microglia, advances of TREM2 signaling, and the cytokine paradox in Alzheimer's disease are further contributions to this article. Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. This mini review series originated from the 4th Venusberg Meeting on Neuroinflammation held in Bonn, Germany, 7-9th May 2015, presenting updates on innate immunity in acute brain injury and chronic neurodegenerative disorders, such as traumatic brain injury and Alzheimer's disease, on the role of astrocytes and microglia, as well as technical developments that may help elucidate neuroinflammatory mechanisms and establish clinical relevance. In this meeting report, a brief overview on physiological and pathological microglia morphology is followed by a synopsis on PGE2 receptors, insights into the role of arginine metabolism and further relevant aspects of neuroinflammation in various clinical settings, and concluded by a presentation of technical challenges and solutions when working with microglia cultures. Microglial ontogeny and induced pluripotent stem cell-derived microglia, advances of TREM2 signaling, and the cytokine paradox in Alzheimer's disease are further contributions to this article.
- Published
- 2016
11. Disease-related microglia heterogeneity in the hippocampus of Alzheimer's disease, dementia with Lewy bodies, and hippocampal sclerosis of aging.
- Author
-
Bachstetter, Adam D., Van Eldik, Linda J., Schmitt, Frederick A., Neltner, Janna H., Ighodaro, Eseosa T., Webster, Scott J., Patel, Ela, Abner, Erin L., Kryscio, Richard J., and Nelson, Peter T.
- Subjects
- *
MICROGLIA , *ALZHEIMER'S disease , *LEWY body dementia - Abstract
Introduction: Neuropathological, genetic, and biochemical studies have provided support for the hypothesis that microglia participate in Alzheimer's disease (AD) pathogenesis. Despite the extensive characterization of AD microglia, there are still many unanswered questions, and little is known about microglial morphology in other common forms of age-related dementia: particularly, dementia with Lewy bodies (DLB) and hippocampal sclerosis of aging (HS-Aging). In addition, no prior studies have attempted to compare and contrast the microglia morphology in the hippocampus of various neurodegenerative conditions. Results: Here we studied cases with pathologically-confirmed AD (n =7), HS-Aging (n = 7), AD + HS-aging (n = 4), DLB (n = 12), and normal (cognitively intact) controls (NC) (n = 9) from the University of Kentucky Alzheimer's Disease Center autopsy cohort. We defined five microglia morphological phenotypes in the autopsy samples: ramified, hypertrophic, dystrophic, rod-shaped, and amoeboid. The Aperio ScanScope digital neuropathological tool was used along with two well-known microglial markers: IBA1 (a marker for both resting and activated microglia) and CD68 (a lysosomal marker in macrophages/microglia associated with phagocytic cells). Hippocampal staining analyses included studies of subregions within the hippocampal formation and nearby white matter. Using these tools and methods, we describe variation in microglial characteristics that show some degree of disease specificity, including, (1) increased microglia density and number in HS-aging and AD + HS-aging; (2) low microglia density in DLB; (3) increased number of dystrophic microglia in HS-aging; and (4) increased proportion of dystrophic to all microglia in DLB. Conclusions: We conclude that variations in morphologies among microglial cells, and cells of macrophage lineage, can help guide future work connecting neuroinflammatory mechanisms with specific neurodegenerative disease subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective.
- Author
-
Tai, Leon M., Ghura, Shivesh, Koster, Kevin P., Liakaite, Vaiva, Maienschein‐Cline, Mark, Kanabar, Pinal, Collins, Nicole, Ben‐Aissa, Manel, Lei, Arden Zhengdeng, Bahroos, Neil, Green, Stefan J., Hendrickson, Bill, Van Eldik, Linda J., and LaDu, Mary Jo
- Subjects
GENETICS of Alzheimer's disease ,INFLAMMATORY mediators ,DISEASE progression ,BRAIN diseases ,TOLL-like receptors ,GENETICS - Abstract
Chronic glial activation and neuroinflammation induced by the amyloid-β peptide (Aβ) contribute to Alzheimer's disease ( AD) pathology. APOE4 is the greatest AD-genetic risk factor; increasing risk up to 12-fold compared to APOE3, with APOE4-specific neuroinflammation an important component of this risk. This editorial review discusses the role of APOE in inflammation and AD, via a literature review, presentation of novel data on Aβ-induced neuroinflammation, and discussion of future research directions. The complexity of chronic neuroinflammation, including multiple detrimental and beneficial effects occurring in a temporal and cell-specific manner, has resulted in conflicting functional data for virtually every inflammatory mediator. Defining a neuroinflammatory phenotype ( NIP) is one way to address this issue, focusing on profiling the changes in inflammatory mediator expression during disease progression. Although many studies have shown that APOE4 induces a detrimental NIP in peripheral inflammation and Aβ-independent neuroinflammation, data for APOE-modulated Aβ-induced neuroinflammation are surprisingly limited. We present data supporting the hypothesis that impaired apoE4 function modulates Aβ-induced effects on inflammatory receptor signaling, including amplification of detrimental (toll-like receptor 4-p38α) and suppression of beneficial ( IL-4R-nuclear receptor) pathways. To ultimately develop APOE genotype-specific therapeutics, it is critical that future studies define the dynamic NIP profile and pathways that underlie APOE-modulated chronic neuroinflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Closed Head Injury in an Age-Related Alzheimer Mouse Model Leads to an Altered Neuroinflammatory Response and Persistent Cognitive Impairment.
- Author
-
Webster, Scott J., Van Eldik, Linda J., Watterson, D. Martin, and Bachstetter, Adam D.
- Subjects
- *
ALZHEIMER'S disease diagnosis , *ANIMAL models of Alzheimer's disease , *HEAD injuries , *PATHOLOGICAL physiology , *MILD cognitive impairment , *ALZHEIMER'S disease treatment , *THERAPEUTICS - Abstract
Epidemiological studies have associated increased risk of Alzheimer's disease (AD)-related clinical symptoms with a medical history of head injury. Currently, little is known about pathophysiology mechanisms linked to this association. Persistent neuroinflammation is one outcome observed in patients after a single head injury. Neuroinflammation is also present early in relevant brain regions duringAD pathology progression. In addition, previous mechanistic studies in animal models link neuroinflammation as a contributor to neuropathology and cognitive impairment in traumatic brain injury (TBI) or AD-related models. Therefore, we explored the potential interplay of neuroinflammatory responses in TBI and AD by analysis of the temporal neuroinflammatory changes after TBI in an AD model, the APP/PS1 knock-in (KI) mouse. Discrete temporal aspects of astrocyte, cytokine, and chemokine responses in the injured KI mice were delayed compared with the injured wild-type mice, with a peak neuroinflammatory response in the injured KI mice occurring at 7 d after injury. The neuroinflammatory responses were more persistent in the injured KI mice, leading to a chronic neuroinflammation. At late time points after injury, KI mice exhibited a significant impairment in radial arm water maze performance compared with sham KI mice or injured wild-type mice. Intervention with a small-molecule experimental therapeutic (MW151) that selectively attenuates proinflammatory cytokine production yielded improved cognitive behavior outcomes, consistent with a link between neuroinflammatory responses and altered risk for AD-associated pathology changes with head injury. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic.
- Author
-
Bachstetter, Adam D., Webster, Scott J., Goulding, Danielle S., Morton, Jonathan E., Watterson, D. Martin, and Van Eldik, Linda J.
- Subjects
BRAIN injuries ,HEAD injuries ,LABORATORY mice ,CYTOKINES ,MILD cognitive impairment - Abstract
Background: Evidence from clinical studies and preclinical animal models suggests that proinflammatory cytokine overproduction is a potential driving force for pathology progression in traumatic brain injury (TBI). This raises the possibility that selective targeting of the overactive cytokine response, a component of the neuroinflammation that contributes to neuronal dysfunction, may be a useful therapeutic approach. MW151 is a CNS-penetrant, small molecule experimental therapeutic that selectively restores injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. We previously reported that MW151 administered post-injury (p.i.) is efficacious in a closed head injury (CHI) model of diffuse TBI in mice. Here we test dose dependence of MW151 to suppress the target mechanism (proinflammatory cytokine up-regulation), and explore the therapeutic window for MW151 efficacy. Methods: We examined suppression of the acute cytokine surge when MW151 was administered at different times post-injury and the dose-dependence of cytokine suppression. We also tested a more prolonged treatment with MW151 over the first 7 days post-injury and measured the effects on cognitive impairment and glial activation. Results: MW151 administered up to 6 h post-injury suppressed the acute cytokine surge, in a dose-dependent manner. Administration of MW151 over the first 7 days post-injury rescues the CHI-induced cognitive impairment and reduces glial activation in the focus area of the CHI. Conclusions: Our results identify a clinically relevant time window post-CHI during which MW151 effectively restores cytokine production back towards normal, with a resultant attenuation of downstream cognitive impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain.
- Author
-
Bachstetter, Adam D., Webster, Scott J., Van Eldik, Linda J., and Cambi, Franca
- Subjects
MICROGLIA ,NEUROGLIA ,LEG diseases ,PARALYSIS ,NEURONS - Abstract
Introduction Mutations in proteolipid protein (PLP), the most abundant myelin protein in the CNS, cause the X-linked dysmyelinating leukodystrophies, Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2 (SPG2). Point mutations, deletion, and duplication of the PLP1 gene cause PMD/SPG2 with varying clinical presentation. Deletion of an intronic splicing enhancer (ISEdel) within intron 3 of the PLP1 gene is associated with a mild form of PMD. Clinical and preclinical studies have indicated that mutations in myelin proteins, including PLP, can induce neuroinflammation, but the temporal and spatial onset of the reactive glia response in a clinically relevant mild form of PMD has not been defined. Methods A PLP-ISEdel knockin mouse was used to examine the behavioral and neuroinflammatory consequences of a deletion within intron 3 of the PLP gene, at two time points (two and four months old) early in the pathological progression. Mice were characterized functionally using the open field task, elevated plus maze, and nesting behavior. Quantitative neuropathological analysis was for markers of astrocytes (GFAP), microglia (IBA1, CD68, MHCII) and axons (APP). The Aperio ScanScope was used to generate a digital, high magnification photomicrograph of entire brain sections. These digital slides were used to quantify the immunohistochemical staining in ten different brain regions to assess the regional heterogeneity in the reactive astrocyte and microglial response. Results The PLP-ISEdel mice exhibited behavioral deficits in the open field and nesting behavior at two months, which did not worsen by four months of age. A marker of axonal injury (APP) increased from two months to four months of age. Striking was the robust reactive astrocyte and microglia response which was also progressive. In the two-month-old mice, the astrocyte and microglia reactivity was most apparent in white matter rich regions of the brain. By four months of age the gliosis had become widespread and included both white as well as gray matter regions of the brain. Conclusions Our results indicate, along with other preclinical models of PMD, that an early reactive glia response occurs following mutations in the PLP gene, which may represent a potentially clinically relevant, oligodendrocyte-independent therapeutic target for PMD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.
- Author
-
Bachstetter, Adam D. and Van Eldik, Linda J.
- Subjects
- *
MITOGEN-activated protein kinases , *CENTRAL nervous system diseases , *NEURODEGENERATION , *CYTOKINES , *IMMUNE system - Abstract
Inflammation in the central nervous system (CNS) is a common feature of age-related neurodegenerative diseases. Proinflammatory cytokines, such as IL-1β and TNFα, are produced primarily by cells of the innate immune system, namely microglia in the CNS, and are believed to contribute to the neuronal damage seen in the disease. The p38 mitogen-activated protein kinase (MAPK) is one of the kinase pathways that regulate the production of IL-1β and TNFα. Importantly, small molecule inhibitors of the p38 MAPK family have been developed and show efficacy in blocking the production of IL-1β and TNFα. The p38 family consists of at least four isoforms (p38α, β, γ, δ) encoded by separate genes. Recent studies have begun to demonstrate unique functions of the different isoforms, with p38a being implicated as the key isoform involved in CNS inflammation. Interestingly, there is also emerging evidence that two downstream substrates of p38 may have opposing roles, with MK2 being pro-inflammatory and MSK1/2 being antiinflammatory. This review discusses the properties, function and regulation of the p38 MAPK family as it relates to cytokine production in the CNS. [ABSTRACT FROM AUTHOR]
- Published
- 2010
17. Glial Activation Links Early-Life Seizures and Long-Term Neurologic Dysfunction: Evidence Using a Small Molecule Inhibitor of Proinflammatory Cytokine Upregulation.
- Author
-
Somera-Molina, Kathleen C., Robin, Beverley, Somera, Cherie Ann, Anderson, Christopher, Stine, Christy, Koh, Sookyong, Behanna, Heather A., Van Eldik, Linda J., Watterson, D. Martin, and Wainwright, Mark S.
- Subjects
NEUROGLIA ,CYTOKINES ,IMMUNOREGULATION ,DEVELOPMENTAL disabilities ,SEIZURES (Medicine) ,EPILEPSY - Abstract
Purpose: Early-life seizures increase vulnerability to subsequent neurologic insult. We tested the hypothesis that early-life seizures increase susceptibility to later neurologic injury by causing chronic glial activation. To determine the mechanisms by which glial activation may modulate neurologic injury, we examined both acute changes in proinflammatory cytokines and long-term changes in astrocyte and microglial activation and astrocyte glutamate transporters in a “two-hit” model of kainic acid (KA)-induced seizures. Methods: Postnatal day (P) 15 male rats were administered KA or phosphate buffered saline (PBS). On P45 animals either received a second treatment of KA or PBS. On P55, control (PBS-PBS), early-life seizure (KA-PBS), adult seizure (PBS-KA), and “two-hit” (KA-KA) groups were examined for astrocyte and microglial activation, alteration in glutamate transporters, and expression of the glial protein, clusterin. Results: P15 seizures resulted in an acute increase in hippocampal levels of IL-1β and S100B, followed by behavioral impairment and long-term increases in GFAP and S100B. Animals in the “two-hit” group showed greater microglial activation, neurologic injury, and susceptibility to seizures compared to the adult seizure group. Glutamate transporters increased following seizures but did not differ between these two groups. Treatment with Minozac, a small molecule inhibitor of proinflammatory cytokine upregulation, following early-life seizures prevented both the long-term increase in activated glia and the associated behavioral impairment. Conclusions: These data suggest that glial activation following early-life seizures results in increased susceptibility to seizures in adulthood, in part through priming microglia and enhanced microglial activation. Glial activation may be a novel therapeutic target in pediatric epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
18. Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-β-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration.
- Author
-
Ranaivo, Hantamalala Ralay, Craft, Jeffrey M., Wenhui Hu, Ling Guo, Wing, Laura K., Van Eldik, Linda J., and Watterson, D. Martin
- Subjects
NEUROGLIA ,AMYLOID ,CYTOKINES ,NEURODEGENERATION ,BRAIN - Abstract
A corollary of the neuroinflammation hypothesis is that selective suppression of neurotoxic products produced by excessive glial activation will result in neuroprotection. We report here that daily oral administration to mice of the brain-penetrant compound 4,6- diphenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine (MW01-5-188WH), a selective inhibitor of proinflammatory cytokine production by activated glia, suppressed the human amyloid-β(Aβ) 1-42-induced upregulation of interleukin-1β, tumor necrosis factor-α, and S100B in the hippocampus. Suppression of neuroinflammation was accompanied by restoration of hippocampal synaptic dysfunction markers synaptophysin and postsynaptic density-95 back toward control levels. Consistent with the neuropathophysiological improvements, MW01-5-188WHtherapy attenuated deficits inYmaze behavior, a hippocampal-linked task. Oral MW0 1-5-188WH therapy begun 3 weeks after initiation of intracerebroventricular infusion of human Aβ decreased the numbers of activated astrocytes and microglia and the cytokine levels in the hippocampus without modifying amyloid plaque burden or altering peripheral tissue cytokine upregulation in response to an in vivo inflammatory challenge. The results provide a novel integrative chemical biology proof in support of the neuroinflammation hypothesis of disease progression, demonstrate that neurodegeneration can be attenuated independently of plaque modulation by targeting innate brain proinflammatory cytokine responses, and indicate the feasibility of developing efficacious, safe, and selective therapies for neurodegenerative disorders by targeting key glial activation pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
19. The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain.
- Author
-
Van Eldik, Linda J. and Wainwright, Mark S.
- Subjects
- *
BRAIN damage , *NEUROTROPHINS , *NEUROPHYSIOLOGY , *ASTROCYTES , *CALCIUM-binding proteins - Abstract
Glia play active and vital roles in the CNS, including regulation of brain development, maintenance of cellular homeostasis and reparative responses to acute and chronic neurologic insults. However, in pathological conditions, glial function may be dysregulated resulting in enhanced neuroinflammation and further neurologic injury. The fundamental concept that aberrant regulation of a normally beneficial process may instead result in pathology is exemplified by the properties of the glial-derived protein, S100B. In the developing brain and following acute glial activation in response to injury, S100B acts as a neurotrophic factor and neuronal survival protein. In contrast, overproduction of S100B by activated glia can lead to exacerbation of neuroinflammation and neuronal dysfunction. This duality of S100B actions, both reparative and degenerative, is consistent with the compelling clinical evidence of the association between increases in S100B levels and outcome following brain injury. S100B levels generally correlate with the severity of damage and may have predictive value for adverse neurological outcomes. The cumulative data support the potential of S100B as a biomarker for brain damage, implicate glial activation as a possible treatment target in acute and chronic CNS disorders, and highlight the dual role of glia in the reparative and pathologic responses to neurologic injury. [ABSTRACT FROM AUTHOR]
- Published
- 2003
20. Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease.
- Author
-
Herrup, Karl, Carrillo, Maria C., Schenk, Dale, Cacace, Angela, DeSanti, Susan, Fremeau, Robert, Bhat, Ratan, Glicksman, Marcie, May, Patrick, Swerdlow, Russell, Van Eldik, Linda J., Bain, Lisa J., and Budd, Samantha
- Abstract
Abstract: For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
21. Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug
- Author
-
Karpus, William J., Reynolds, Nathaneal, Behanna, Heather A., Van Eldik, Linda J., and Watterson, D. Martin
- Subjects
- *
ENCEPHALOMYELITIS , *CYTOKINES , *MOLECULAR weights , *DRUG efficacy - Abstract
Abstract: Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated, autoimmune disease of the central nervous system (CNS) that serves as a model for various cellular and molecular aspects of the human disease, multiple sclerosis (MS). Although EAE has long been considered a T cell-mediated disease, macrophages play a role in disease pathogenesis and are known to accumulate in the CNS under the control of chemokines. In the present report we demonstrate that mice induced to develop EAE were treated with a small molecular weight molecule that suppresses proinflammatory cytokine production which resulted in significantly decreased clinical EAE, CNS CCL2 expression and CNS macrophage accumulation. These results demonstrate the efficacy of a novel class of therapeutic molecules for CNS demyelinating disease. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
22. IL-1β LEVELS AFTER TBI CAN BE INHIBITED WITH THE THERAPEUTIC MW151, WITHOUT AFFECTING MICROGLIAL PHYSIOLOGICAL RESPONSES.
- Author
-
Späni, Claudia, Bachstetter, Adam D., Zhengqiu Zhou, Goulding, Danielle S., Conley, Alyssa N., and Van Eldik, Linda J.
- Subjects
- *
INTERLEUKIN-1 , *IMMUNE response , *BRAIN injuries - Abstract
Many disorders of the central nervous system (CNS) involve neuroinflammation, an inflammatory/immune response in the brain. Following traumatic brain injury (TBI), dysregulated neuroinflammatory responses are thought to contribute to neurological damage and cognitive deficits in part through an increased production of proinflammatory cytokines such as interleukin-1 beta (IL-1β). Addressing these damaging proinflammatory processes without affecting endogenous recovery responses has therefore yielded a potential intervention target. This study investigated the use of MW151, a CNS-penetrant, small molecule experimental therapeutic that restores overproduction of proinflammatory cytokines towards homeostasis without general immunosuppression when administered post-injury in multiple TBI models. In a midline fluid percussion model of diffuse brain injury in mice administration of a low dose (0.5-5.0 mg/kg) of MW151 suppressed IL-1β levels in the cortex. Reactive astrocyte and microglia morphological responses were not affected. In an in vitro study the BV-2 microglial cell line was used to demonstrate that phagocytosis, proliferation, and migration of microglial cells was not affected by treatment with MW151. These results demonstrate that the use of selective therapeutic modulation is a feasible tool to target the increase of the proinflammatory cytokine IL-1β without affecting physiological responses of glial cells. [ABSTRACT FROM AUTHOR]
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.